Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
주식 순위 #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
주가
$150.78
마지막 동기화: 2026-09-18
시가총액
$187.20B
변동 (1일)
-0.08%
변동 (1년)
32.15%
국가
US
거래 Gilead Sciences, Inc. (GILD)

카테고리

Gilead Sciences, Inc. (GILD)의 P/S 비율
September 2026 기준 P/S 비율 TTM: 5.97
Gilead Sciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 5.97입니다. 2024년 말 기준 P/S 비율은 4.01였습니다.
Gilead Sciences, Inc.의 P/S 비율 기록 (2000 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 5.97 15.00%
2025 5.19 29.46%
2024 4.01 7.44%
2023 3.73 -5.59%
2022 3.95 18.24%
2021 3.34 12.60%
2020 2.97 -19.31%
2019 3.68 0.19%
2018 3.67 2.31%
2017 3.59 13.67%
2016 3.16 -30.48%
2015 4.54 -21.25%
2014 5.76 -43.76%
2013 10.25 78.72%
2012 5.73 51.64%
2011 3.78 -3.10%
2010 3.90 -30.11%
2009 5.58 -36.72%
2008 8.82 -12.66%
2007 10.10 2.59%
2006 9.85 -16.34%
2005 11.77 3.14%
2004 11.41 -15.54%
2003 13.51 -5.12%
2002 14.24 -46.77%
2001 26.76 38.69%
2000 19.29 0.00%
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
13.45 125.34%
US
6.55 9.80%
US
7.18 20.32%
US
4.66 -21.95%
CH
5.39 -9.74%
US